Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome [7]

Journal of Medical Genetics

Volumn 39, Issue 12, 2002, Pages 941-944

  Evans, D Gareth R ^a   Birch, J M ^b   Thorneycroft, M ^c   McGown, G ^c   Lalloo, F ^a   Varley, J M ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Royal Manchester Children's University Hospital   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENE PRODUCT; PROTEIN P53; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; BLOOD SAMPLING; BREAST CANCER; CLINICAL ARTICLE; EXON; FAMILIAL CANCER; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GERM LINE; HUMAN; LETTER; PRIORITY JOURNAL; PROMOTER REGION; RELATIVE; SARCOMA; SYNDROME DELINEATION; TP53 GENE;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENES, P53; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; SARCOMA;

EID: 0036917852     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (32)

1. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-52.
2. Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA 1982;247:2692-4.
3. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62. [AQ1]
4. Birch JM, Hartley AL, Marsden HB, Harris M, Swindell R. Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer 1984;49:325-31.
5. Birch JM, Hartley AL, Blair V, Kelsey AH, Harris M, Teare MD, Morris-Jones PH. Cancer in the families of children with soft tissue sarcoma. Cancer 1990;66:2239-48.
6. Birch JM, Hartley AL, Blair V, Kelsey AM, Harris M, Teare MD, Jones PH. Identification of factors associated with high breast cancer risk in the mothers of children with soft tissue sarcoma. J Clin Oncol 1990;8:583-90.
7. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DGR, Birch JM. Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res 1997;57;3245-52.
8. Varley JM, McGown G, Thorncroft M, Evans DGR, Kelsey AM, Birch JM. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 1999;65:995-1006.
9. McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen AL, Yan YX, Russo C, Sato J, Barbier N, Miser J, Malkin D, Gebhardt MC. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994;12:925-30.
10. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, Weichselbaum RR, Yandell DW. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992;326:1301-8.
11. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995;95:1606-11.
12. Ayan I, Luca JW, Jaffe N. De novo germline mutations of the p53 gene in young children with sarcomas. Oncol Rep 1997;4:679-83.
13. Birch JM, Alston RD, McNally RJQ, Evans DGR, Kelsey AM, Harris M, Eden OB, Varley JM. Relative Frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001;20:4621-8.
14. Chompret A Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frebourg T, Lemerle J, Bonaiti-Pellie C, Feunteun J. p53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000;82:1932-7
15. Office for National Statistics. Annual Report on Cancer Registration Statistics (MB1/29), England, 1998.
16. Miller BA, Feuer DJ, Hankey BF. Recent incidence trends for breast cancer in women and relevance of early detection: An update. CA Cancer J Clin 1993;43:27-41.
17. Birch JM, Hartley AL, Tricker KJ, Tricker KJ, Prosser J, Kelsey AM, Harris M, Morris-Jones PH, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann J, Martin J. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-304.
18. Varley JM, Thorncroft M, McGown G, Tricker K, Birch JM, Evans DGR. A novel deletion within exon 6 of TP53 in a family with Li Fraumeni-like syndrome, and LOH in a benign lesion from a mutation carrier. Cancer Genet Cytogenet 1996;90:14-16.
19. Kovar H, Auinger A, Jug G, Müller T, Pillwein K. p53 mosaicism with an exon 8 germline mutation in the founder of a cancer-prone pedigree. Oncogene 1992;7:2169-73.
20. Evans DGR, Truman L, Wallace A, Strachan, T. Mosaicism in classical NF2: A common mechanism for sporadic disease in tumour prone syndromes? Am J Hum Genet 1998;63:727-36.
21. Meijers-Heljboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton DF, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber BL, Rahman N, Stratton MR.. Low penetrance breast cancer susceptibility due to CHK2 1100delC in non-carriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
22. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JA, Haber DA Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
23. Børresen AL, Andersen TI, Garber J. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992;52:3234-6.
24. Prosser J, Porter D, Coles C, Condie A, Thompson AM, Chetty U, Steel CM, Evans HJ. Constitutional p53 mutation in a non-Li-Fraumeni cancer family. Br J Cancer 1992;65:527-8.
25. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacoma L, Vogelstein B, Davidson N. Inherited p53 gene mutations in breast cancer. Cancer Res 1992;52:2984-6.
26. Rapakko K, Allinen M, Syrjakoski, K, Vahteristo P, Huusko P, Vahakangas K, Eerola H, Kainu T, Kallioniemi OP, Nevanlinna H, Winqvist R. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 2001;84:116-19.
27. Lalloo F, Varley J, Ellis D, O'Dair L, Pharoah P, Evans DGR, and the Early Onset Breast Cancer Study Group. Family history is predictive of pathogenic mutations in BRCA1, BRCA2 and TP53 with high penetrance in a population based study of very early onset breast cancer. Lancet (in press).
28. Bennett KE, Howell A, Evans DGR, Birch JM. A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients. Br J Cancer 2002;86:718-22.
29. Malkin D, Friend SH, Li FP, Strong LC. Germ-line mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1997;336:734.
30. Chompret A, Abel A, Stoppa-Lyonnet D, Brugieres L, Pages S, Feunten J, Bonaite-Pellie C. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001;38:43-7.
31. Evans DGR, Maher ER, Macleod R, Davies DR, Craufurd D. Uptake of genetic testing for cancer predisposition. J Med Genet 1997;34:746-8.
32. Schneider KA, Patenaude AF, Garber JE. Testing for cancer genes: Decisions, decisions. Nat Med 1994;1:302-3.